Cargando…

Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases

Metastatic uveal melanoma (mUM) is an advanced ocular malignancy characterized by a hepatotropic pattern of spread. As the incidence of brain metastases (BM) in mUM patients has been thought to be low, routine CNS surveillance has not been recommended. Notably, no formal assessment of BM incidence i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Alexander Z., Uriel, Matan, Porcu, Agata, Manos, Michael P., Mercurio, Ann C., Caplan, Michael M., Hulse, Liam, Seedor, Rino S., Holovatska, Marta, Francis, Jasmine, Khan, Shaheer A., McDonnell, Diana E., Bogomolny, Dmitry, Sato, Takami, Marr, Brian P., Haq, Rizwan, Orloff, Marlana, Shoushtari, Alexander, Carvajal, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540230/
https://www.ncbi.nlm.nih.gov/pubmed/36212499
http://dx.doi.org/10.3389/fonc.2022.961517
_version_ 1784803665356259328
author Wei, Alexander Z.
Uriel, Matan
Porcu, Agata
Manos, Michael P.
Mercurio, Ann C.
Caplan, Michael M.
Hulse, Liam
Seedor, Rino S.
Holovatska, Marta
Francis, Jasmine
Khan, Shaheer A.
McDonnell, Diana E.
Bogomolny, Dmitry
Sato, Takami
Marr, Brian P.
Haq, Rizwan
Orloff, Marlana
Shoushtari, Alexander
Carvajal, Richard D.
author_facet Wei, Alexander Z.
Uriel, Matan
Porcu, Agata
Manos, Michael P.
Mercurio, Ann C.
Caplan, Michael M.
Hulse, Liam
Seedor, Rino S.
Holovatska, Marta
Francis, Jasmine
Khan, Shaheer A.
McDonnell, Diana E.
Bogomolny, Dmitry
Sato, Takami
Marr, Brian P.
Haq, Rizwan
Orloff, Marlana
Shoushtari, Alexander
Carvajal, Richard D.
author_sort Wei, Alexander Z.
collection PubMed
description Metastatic uveal melanoma (mUM) is an advanced ocular malignancy characterized by a hepatotropic pattern of spread. As the incidence of brain metastases (BM) in mUM patients has been thought to be low, routine CNS surveillance has not been recommended. Notably, no formal assessment of BM incidence in mUM has to date been published to support this clinical practice. We aimed to determine the true rate of BM in mUM and to clarify the clinical and genomic risk factors associated with BM patients through a collaborative multicenter, retrospective research effort. Data collected from 1,845 mUM patients in databases across four NCI-designated comprehensive cancer centers from 2006-2021 were retrospectively analyzed to identify patients with BM. Brain imaging in most cases were performed due to onset of neurological symptoms and not for routine surveillance. An analysis of demographics, therapies, gene expression profile, tumor next generation sequencing (NGS) data, time to metastasis (brain or other), and survival in the BM cohort was completed. 116/1,845 (6.3%) mUM patients were identified with BM. The median age at time of UM diagnosis was 54 years old (range: 18-77). The median time to any metastasis was 4.2 years (range: 0-30.8). The most common initial metastatic site was the liver (75.9%). 15/116 (12.9%) BM patients presented with BM at the time of initial metastatic diagnosis. Median survival after a diagnosis of BM was 7.6 months (range: 0.4-73.9). The median number of organs involved at time of BM diagnosis was 3 (range: 1-9). DecisionDX-UM profiling was completed on 13 patients: 10-Class 2, 2-Class 1B, and 1-Class 1A. NGS and cytogenetic data were available for 34 and 21 patients, respectively. BM was identified in 6.3% of mUM cases and was associated with high disease burden and a median survival of under 8 months once diagnosed. Since most patients in this cohort were symptomatic, the incidence of asymptomatic BM remains unknown. These data suggest the use of routine brain imaging in all mUM patients at risk for developing BM for early detection.
format Online
Article
Text
id pubmed-9540230
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95402302022-10-08 Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases Wei, Alexander Z. Uriel, Matan Porcu, Agata Manos, Michael P. Mercurio, Ann C. Caplan, Michael M. Hulse, Liam Seedor, Rino S. Holovatska, Marta Francis, Jasmine Khan, Shaheer A. McDonnell, Diana E. Bogomolny, Dmitry Sato, Takami Marr, Brian P. Haq, Rizwan Orloff, Marlana Shoushtari, Alexander Carvajal, Richard D. Front Oncol Oncology Metastatic uveal melanoma (mUM) is an advanced ocular malignancy characterized by a hepatotropic pattern of spread. As the incidence of brain metastases (BM) in mUM patients has been thought to be low, routine CNS surveillance has not been recommended. Notably, no formal assessment of BM incidence in mUM has to date been published to support this clinical practice. We aimed to determine the true rate of BM in mUM and to clarify the clinical and genomic risk factors associated with BM patients through a collaborative multicenter, retrospective research effort. Data collected from 1,845 mUM patients in databases across four NCI-designated comprehensive cancer centers from 2006-2021 were retrospectively analyzed to identify patients with BM. Brain imaging in most cases were performed due to onset of neurological symptoms and not for routine surveillance. An analysis of demographics, therapies, gene expression profile, tumor next generation sequencing (NGS) data, time to metastasis (brain or other), and survival in the BM cohort was completed. 116/1,845 (6.3%) mUM patients were identified with BM. The median age at time of UM diagnosis was 54 years old (range: 18-77). The median time to any metastasis was 4.2 years (range: 0-30.8). The most common initial metastatic site was the liver (75.9%). 15/116 (12.9%) BM patients presented with BM at the time of initial metastatic diagnosis. Median survival after a diagnosis of BM was 7.6 months (range: 0.4-73.9). The median number of organs involved at time of BM diagnosis was 3 (range: 1-9). DecisionDX-UM profiling was completed on 13 patients: 10-Class 2, 2-Class 1B, and 1-Class 1A. NGS and cytogenetic data were available for 34 and 21 patients, respectively. BM was identified in 6.3% of mUM cases and was associated with high disease burden and a median survival of under 8 months once diagnosed. Since most patients in this cohort were symptomatic, the incidence of asymptomatic BM remains unknown. These data suggest the use of routine brain imaging in all mUM patients at risk for developing BM for early detection. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9540230/ /pubmed/36212499 http://dx.doi.org/10.3389/fonc.2022.961517 Text en Copyright © 2022 Wei, Uriel, Porcu, Manos, Mercurio, Caplan, Hulse, Seedor, Holovatska, Francis, Khan, McDonnell, Bogomolny, Sato, Marr, Haq, Orloff, Shoushtari and Carvajal https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wei, Alexander Z.
Uriel, Matan
Porcu, Agata
Manos, Michael P.
Mercurio, Ann C.
Caplan, Michael M.
Hulse, Liam
Seedor, Rino S.
Holovatska, Marta
Francis, Jasmine
Khan, Shaheer A.
McDonnell, Diana E.
Bogomolny, Dmitry
Sato, Takami
Marr, Brian P.
Haq, Rizwan
Orloff, Marlana
Shoushtari, Alexander
Carvajal, Richard D.
Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
title Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
title_full Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
title_fullStr Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
title_full_unstemmed Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
title_short Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
title_sort characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540230/
https://www.ncbi.nlm.nih.gov/pubmed/36212499
http://dx.doi.org/10.3389/fonc.2022.961517
work_keys_str_mv AT weialexanderz characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT urielmatan characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT porcuagata characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT manosmichaelp characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT mercurioannc characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT caplanmichaelm characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT hulseliam characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT seedorrinos characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT holovatskamarta characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT francisjasmine characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT khanshaheera characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT mcdonnelldianae characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT bogomolnydmitry characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT satotakami characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT marrbrianp characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT haqrizwan characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT orloffmarlana characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT shoushtarialexander characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases
AT carvajalrichardd characterizingmetastaticuvealmelanomapatientswhodevelopsymptomaticbrainmetastases